MYELOF
MCID: MYL005
MIFTS: 67

Myelofibrosis (MYELOF)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Myelofibrosis

MalaCards integrated aliases for Myelofibrosis:

Name: Myelofibrosis 56 12 74 52 73 36 29 54 6 15 37 39 71
Primary Myelofibrosis 12 52 25 58 54 43 17 71
Agnogenic Myeloid Metaplasia 12 52 25 58 73 54
Idiopathic Myelofibrosis 52 25 58 73 54
Myelofibrosis with Myeloid Metaplasia 25 58 73 6
Myeloid Metaplasia 52 25 54 71
Osteomyelofibrosis 58 71 32
Myelofibrosis with Myeloid Metaplasia, Somatic 56 13
Megakaryocytic Myelosclerosis 12 71
Myelosclerosis 12 73
Agnogenic Myeloid Metaplasia with Myelofibrosis 73
Myelosclerosis with Myeloid Metaplasia 73
Chronic Idiopathic Myelofibrosis 25
Myelofibrosis, Somatic 56
Bone Marrow Fibrosis 12
Aleukemic Myelosis 12
Myelof 73
Ammm 73
Mmm 73

Characteristics:

Orphanet epidemiological data:

58
primary myelofibrosis
Prevalence: 1-9/100000 (Europe); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation

Miscellaneous:
onset first weeks of life


HPO:

31

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Myelofibrosis

Genetics Home Reference : 25 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis. Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising. Because blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.

MalaCards based summary : Myelofibrosis, also known as primary myelofibrosis, is related to myeloproliferative neoplasm and megakaryocytic leukemia. An important gene associated with Myelofibrosis is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are JAK-STAT signaling pathway and Response to elevated platelet cytosolic Ca2+. The drugs Parathyroid hormone and Calcium have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

NIH Rare Diseases : 52 Myelofibrosis is a disorder of the spongy tissue inside the bone (bone marrow) that contains the stem cells that will form blood cells . In myelofibrosis, the bone marrow is replaced by fibrous (scar) tissue. When the bone marrow is scarred, it cannot make enough blood cells. This leads to anemia , weakness, fatigue, and often, swelling of the liver and spleen. The disorder occurs when blood stem cells develop somatic mutations in the JAK2 , MPL , CALR , and TET2 genes . Other genes may also be involved. The disorder is generally not inherited because this type of mutation does not affect the reproductive cells (sperm and egg) only certain cells of the body (somatic). Although myelofibrosis can occur at any age, it typically develops after the age of 50 years. In most cases, myelofibrosis gets progressively worse. Treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy , radiation therapy , and surgery. Bone marrow or stem cell transplant may improve symptoms, and may cure the disease.

KEGG : 36 Myelofibrosis (MF), one of the three classic Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs), is characterized by symptoms mainly derived from anemia and splenomegaly and constitutional symptoms and associated with a median survival around 6 years. Most MPN patients harbor an acquired mutation in the hemopoietic cells, the V617F mutation, located in the pseudokinase domain of the JAK2 gene. This mutation results in a gain of function, i.e., in the constitutive activation of the JAK-STAT pathway, which plays an important role in the proliferation, differentiation, and survival of the hemopoietic cells, as well as in the immune function. Besides, a minority of patients with MF (most of them negative for the JAK2 mutation) harbor other JAK-STAT-activating mutation, the MPL mutation, in the gene of the receptor of the thrombopoietin. Recently, mutations in the CALR gene have been described in 86% of cases with primary MF that are negative for JAK2 or MPL mutations. CALR mutation also showed cytokine independent growth of cells due to activation of STAT5 involved with the JAK-STAT pathway but its exact role in MPN remains to be clarified.

UniProtKB/Swiss-Prot : 73 Myelofibrosis: A disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Myelofibrosis with myeloid metaplasia: A chronic myeloproliferative disorder characterized by replacement of the bone marrow by fibrous tissue, extramedullary hematopoiesis, anemia, leukoerythroblastosis and hepatosplenomegaly.

Wikipedia : 74 Primary myelofibrosis is a relatively rare bone marrow/blood cancer. It is currently classified as a... more...

More information from OMIM: 254450

Related Diseases for Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 624, show less)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 33.4 U2AF1 THPO TET2 SH2B3 MPL KIT
2 megakaryocytic leukemia 33.3 U2AF1 THPO JAK2 GATA1
3 polycythemia vera 33.3 THPO TET2 MPL KIT JAK2 HMGA2
4 splenomegaly 32.6 MPL JAK2 EPO
5 essential thrombocythemia 32.5 U2AF1 THPO TET2 SH2B3 MPL MIR223
6 polycythemia 32.3 THPO TET2 SH2B3 MPL JAK2 EPO
7 pancytopenia 32.0 U2AF1 THPO MPL MPIG6B KIT EPO
8 thrombocytosis 32.0 U2AF1 THPO TET2 MPL JAK2 EPO
9 thrombocytopenia 32.0 U2AF1 THPO MPL MPIG6B JAK2 GATA1
10 leukemia 31.8 U2AF1 THPO MPL KIT JAK2 CDKN2B-AS1
11 acute leukemia 31.8 THPO KIT JAK2 GATA1
12 deficiency anemia 31.7 U2AF1 THPO SH2B3 MPL JAK2 GATA1
13 neutropenia 31.7 THPO MPL EPO CD177
14 myelodysplastic syndrome 31.6 U2AF1 THPO TET2 MPL MEG3 KIT
15 refractory anemia 31.4 TET2 MPL EPO
16 chronic myelomonocytic leukemia 31.4 U2AF1 TET2 MPL KIT JAK2 CALR
17 myeloma, multiple 31.4 U2AF1 MEG3 KIT JAK2 FGF2 EPO
18 mastocytosis 31.4 TET2 KIT JAK2
19 systemic mastocytosis 31.3 TET2 KIT JAK2
20 hemoglobinuria 31.2 THPO MPL EPO
21 aplastic anemia 31.1 U2AF1 THPO TET2 MPL GATA1 FGF2
22 budd-chiari syndrome 31.1 MPL JAK2 CALR
23 acquired polycythemia 31.0 MPL JAK2 EPO
24 portal vein thrombosis 30.9 MPL JAK2 CALR
25 hypersplenism 30.9 THPO EPO BMP6
26 erythroleukemia, familial 30.8 GATA1 EPO
27 chronic neutrophilic leukemia 30.8 U2AF1 TET2 JAK2 CALR
28 chronic eosinophilic leukemia 30.8 U2AF1 TET2 KIT JAK2
29 myelophthisic anemia 30.7 U2AF1 TET2 SH2B3 MPL JAK2 EPO
30 splenic sequestration 30.6 THPO MPL EPO
31 thrombocythemia 1 30.6 THPO SH2B3 MPL CALR
32 erythrocytosis, familial, 1 30.5 SH2B3 JAK2 EPO
33 myelodysplastic/myeloproliferative neoplasm 30.5 U2AF1 TET2 JAK2
34 chronic leukemia 30.5 U2AF1 TET2 KIT JAK2
35 indolent systemic mastocytosis 30.5 U2AF1 TET2 KIT
36 diamond-blackfan anemia 30.5 U2AF1 THPO MPL JAK2 GATA1 EPO
37 leukemia, chronic myeloid 30.4 U2AF1 THPO MPL MIR223 MEG3 KIT
38 blood platelet disease 30.4 U2AF1 THPO MPL KIT JAK2 GATA1
39 primary polycythemia 30.4 U2AF1 THPO TET2 SH2B3 MPL JAK2
40 leukemia, acute myeloid 30.3 WT1-AS U2AF1 THPO TET2 MPL MIR223
41 leukemia, acute lymphoblastic 30.3 U2AF1 THPO MPL MIR223 KIT JAK2
42 glioma 30.1 MIR146B MEG3 FGF2 CDKN2B-AS1
43 acquired von willebrand syndrome 30.0 U2AF1 JAK2
44 hematologic cancer 30.0 U2AF1 THPO MPL MIR223 MIR146B KIT
45 leukemia, chronic lymphocytic 29.9 U2AF1 THPO MIR223 KIT JAK2
46 acute panmyelosis with myelofibrosis 12.8
47 thrombocytopenia, anemia, and myelofibrosis 12.5
48 cellular phase chronic idiopathic myelofibrosis 12.3
49 thrombocytopenia 6 12.1
50 gray platelet syndrome 11.9
51 neutropenia, severe congenital, 5, autosomal recessive 11.5
52 specific granule deficiency 2 11.3
53 bleeding disorder, platelet-type, 17 11.2
54 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.7 KIT JAK2 EPO
55 extracutaneous mastocytoma 10.7 U2AF1 TET2 KIT
56 thrombocytopenia 3 10.7 THPO MPL
57 sm-ahnmd 10.7 U2AF1 TET2 KIT JAK2
58 systemic mastocytosis with associated hematologic neoplasm 10.7 TET2 KIT
59 myeloproliferative syndrome, transient 10.7 U2AF1 THPO MPL GATA1
60 amegakaryocytic thrombocytopenia, congenital 10.7 U2AF1 THPO MPL JAK2 GATA1
61 atypical chronic myeloid leukemia 10.7 U2AF1 TET2 JAK2
62 retinitis pigmentosa and erythrocytic microcytosis 10.7 JAK2 EPO
63 juvenile nasopharyngeal angiofibroma 10.7 KIT FGF2 BMP6
64 dyskeratosis congenita, autosomal dominant 6 10.7 THPO MPL
65 refractory cytopenia with multilineage dysplasia 10.7 U2AF1 TET2
66 blood coagulation disease 10.7 U2AF1 THPO MPL KIT JAK2 EPO
67 deep leiomyoma 10.7 KIT CD177
68 autoimmune hepatitis type 1 10.6 SH2B3 BMP6
69 myeloid leukemia 10.6
70 acquired thrombocytopenia 10.6 THPO MPL
71 endosteal hyperostosis, autosomal dominant 10.6
72 inflammatory bowel disease 27 10.6 GATA1 EPO
73 myoma 10.6 KIT HMGA2 EPO
74 thrombocytopenia 1 10.6 THPO GATA1
75 bone marrow cancer 10.6 U2AF1 THPO TET2 MPL KIT JAK2
76 core binding factor acute myeloid leukemia 10.5 KIT JAK2
77 mesenchymoma 10.5 KIT HMGA2
78 dupuytren contracture 10.5 FGF2 BMP6
79 pancreatic adenocarcinoma 10.5 U2AF1 KIT JAK2 FGF2 BMP6
80 graft-versus-host disease 10.5
81 chromosomal triplication 10.5
82 portal hypertension 10.5
83 wilms tumor 1 10.5 WT1-AS U2AF1 MEG3 KIT GATA1
84 lupus erythematosus 10.4
85 systemic lupus erythematosus 10.4
86 lymphocytic leukemia 10.4
87 acute graft versus host disease 10.4
88 lymphoma 10.3
89 pulmonary hypertension 10.3
90 hemosiderosis 10.3
91 autoimmune disease 10.3
92 rare hereditary hemochromatosis 10.3
93 rickets 10.3
94 melanoma 10.3
95 myeloid sarcoma 10.3
96 thrombosis 10.3
97 hemolytic anemia 10.3
98 kaposi sarcoma 10.3
99 purpura 10.2
100 severe combined immunodeficiency 10.2
101 47,xyy 10.2
102 thrombophilia due to thrombin defect 10.2
103 varicose veins 10.2
104 pyoderma 10.2
105 pyoderma gangrenosum 10.2
106 primary hypertrophic osteoarthropathy 10.2
107 hypereosinophilic syndrome 10.2
108 trisomy 1q 10.2
109 benign mesothelioma 10.2
110 malignant pleural mesothelioma 10.2
111 idiopathic spinal cord herniation 10.2
112 fibrosis of extraocular muscles, congenital, 1 10.2
113 sarcoma 10.2
114 respiratory failure 10.2
115 spindle cell sarcoma 10.2
116 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
117 hairy cell leukemia 10.2
118 chronic graft versus host disease 10.2
119 thrombocytopenic purpura, autoimmune 10.1
120 anemia, autoimmune hemolytic 10.1
121 thalassemia 10.1
122 esophageal varix 10.1
123 hyperparathyroidism 10.1
124 iron metabolism disease 10.1
125 liver cirrhosis 10.1
126 peripheral nervous system disease 10.1
127 b-cell lymphoma 10.1
128 neuropathy 10.1
129 48,xyyy 10.1
130 temporal arteritis 10.1
131 goiter 10.1
132 amenorrhea 10.1
133 candidiasis 10.1
134 nocardiosis 10.1
135 hepatic vascular disease 10.1
136 myocarditis 10.1
137 vein disease 10.1
138 47, xxy 10.1
139 partial deletion of the long arm of chromosome 20 10.1
140 lymphedema 10.1
141 neutrophilia, hereditary 10.1 U2AF1 MIR223 JAK2
142 neurofibromatosis, type i 10.1 KIT CDKN2B-AS1
143 peripheral t-cell lymphoma 10.1
144 histiocytosis 10.1
145 amyloidosis 10.1
146 exanthem 10.1
147 paroxysmal nocturnal hemoglobinuria 10.1
148 nephrotic syndrome 10.1
149 diarrhea 10.1
150 thrombocytopenia due to platelet alloimmunization 10.1
151 kidney disease 10.1
152 red cell aplasia 10.1
153 otitis media 10.1
154 tobacco addiction 10.1
155 aging 10.1
156 opiate dependence 10.1
157 vascular dementia 10.1
158 down syndrome 10.0
159 lymphoma, hodgkin, classic 10.0
160 mycobacterium tuberculosis 1 10.0
161 diffuse large b-cell lymphoma 10.0
162 dermatomyositis 10.0
163 primary biliary cirrhosis 10.0
164 hyperuricemia 10.0
165 splenic infarction 10.0
166 idiopathic interstitial pneumonia 10.0
167 acute kidney failure 10.0
168 pulmonary fibrosis 10.0
169 monocytic leukemia 10.0
170 myeloid splenomegaly 10.0
171 encephalopathy 10.0
172 pik3ca-related overgrowth syndrome 10.0
173 azoospermia 10.0
174 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
175 acute promyelocytic leukemia 10.0
176 hemoglobin h disease 10.0
177 withdrawal disorder 10.0
178 lymphoproliferative syndrome 10.0
179 wernicke encephalopathy 10.0
180 systemic scleroderma 10.0
181 ileus 10.0
182 periostitis 10.0
183 acute monoblastic leukemia 10.0
184 xanthomatosis 10.0
185 chronic erythremia 10.0
186 osteitis fibrosa 10.0
187 bone inflammation disease 10.0
188 miliary tuberculosis 10.0
189 refractory anemia with excess blasts in transformation 10.0
190 leukemia, acute monocytic 10.0
191 scleroderma, familial progressive 10.0
192 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
193 immune deficiency disease 10.0
194 langerhans cell histiocytosis 10.0
195 lymphoma, non-hodgkin, familial 10.0
196 hemophagocytic lymphohistiocytosis 10.0
197 severe congenital neutropenia 10.0
198 bone disease 10.0
199 primary hyperparathyroidism 10.0
200 patau syndrome 10.0
201 gout 10.0
202 urticaria 10.0
203 agammaglobulinemia 10.0
204 glomerulonephritis 10.0
205 pulmonary tuberculosis 10.0
206 parathyroid adenoma 10.0
207 arthritis 10.0
208 vasculitis 10.0
209 bone marrow necrosis 10.0
210 cytokine deficiency 10.0
211 granulocytopenia 10.0
212 thrombotic microangiopathy 10.0
213 mccune-albright syndrome 10.0
214 pyridoxine deficiency 10.0
215 mastocytosis, cutaneous 9.9
216 pulmonary hypertension, primary, 1 9.9
217 dowling-degos disease 1 9.9
218 triiodothyronine receptor auxiliary protein 9.9
219 werner syndrome 9.9
220 wilms tumor 5 9.9
221 alpha-thalassemia 9.9
222 psoriatic arthritis 9.9
223 angiosarcoma 9.9
224 hyperphosphatemia 9.9
225 marginal zone b-cell lymphoma 9.9
226 splenic marginal zone lymphoma 9.9
227 mucositis 9.9
228 bacterial infectious disease 9.9
229 hydronephrosis 9.9
230 secondary hyperparathyroidism 9.9
231 hereditary spherocytosis 9.9
232 renal osteodystrophy 9.9
233 focal segmental glomerulosclerosis 9.9
234 pure red-cell aplasia 9.9
235 polyneuropathy 9.9
236 vascular disease 9.9
237 bilirubin metabolic disorder 9.9
238 antiphospholipid syndrome 9.9
239 urinary tract obstruction 9.9
240 combined t cell and b cell immunodeficiency 9.9
241 connective tissue disease 9.9
242 plasma cell neoplasm 9.9
243 adenoma 9.9
244 juvenile rheumatoid arthritis 9.9
245 ulcerative colitis 9.9
246 evans' syndrome 9.9
247 sideroblastic anemia 9.9
248 macroglobulinemia 9.9
249 alopecia 9.9
250 1q duplications 9.9
251 raynaud phenomenon 9.9
252 headache 9.9
253 tafro syndrome 9.9
254 bladder cancer 9.8
255 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative 9.8
256 asthma 9.8
257 suppression of tumorigenicity 12 9.8
258 omenn syndrome 9.8
259 severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive 9.8
260 leptin deficiency or dysfunction 9.8
261 fibrous dysplasia 9.8
262 childhood acute lymphocytic leukemia 9.8
263 aggressive nk-cell leukemia 9.8
264 poems syndrome 9.8
265 fibrosarcoma 9.8
266 gastritis 9.8
267 cytomegalovirus infection 9.8
268 argyria 9.8
269 precursor t-cell acute lymphoblastic leukemia 9.8
270 breast cancer 9.8
271 factor viii deficiency 9.8
272 nephrolithiasis, calcium oxalate 9.8
273 pernicious anemia 9.8
274 porphyria cutanea tarda 9.8
275 rheumatoid arthritis 9.8
276 myeloperoxidase deficiency 9.8
277 reticulum cell sarcoma 9.8
278 sjogren syndrome 9.8
279 thymoma, familial 9.8
280 hemophilia a 9.8
281 ataxia and polyneuropathy, adult-onset 9.8
282 yemenite deaf-blind hypopigmentation syndrome 9.8
283 sickle cell anemia 9.8
284 pulmonary disease, chronic obstructive 9.8
285 neutrophilic dermatosis, acute febrile 9.8
286 kala-azar 1 9.8
287 gastric cancer 9.8
288 beta-thalassemia 9.8
289 hydrops, lactic acidosis, and sideroblastic anemia 9.8
290 vitamin b12 deficiency 9.8
291 autosomal recessive disease 9.8
292 mantle cell lymphoma 9.8
293 lymphoblastic lymphoma 9.8
294 angioimmunoblastic t-cell lymphoma 9.8
295 ehrlichiosis 9.8
296 osteomalacia 9.8
297 hypoparathyroidism 9.8
298 microcytic anemia 9.8
299 hemopericardium 9.8
300 cardiac tamponade 9.8
301 iron deficiency anemia 9.8
302 pericardial effusion 9.8
303 porphyria 9.8
304 alcoholic liver cirrhosis 9.8
305 hereditary angioedema 9.8
306 panniculitis 9.8
307 angioedema 9.8
308 lymphadenitis 9.8
309 gaucher's disease 9.8
310 cholecystitis 9.8
311 hepatitis b 9.8
312 autoimmune hepatitis 9.8
313 constipation 9.8
314 factor xiii deficiency 9.8
315 macrocytic anemia 9.8
316 sensory peripheral neuropathy 9.8
317 angiodysplasia 9.8
318 basal cell carcinoma 9.8
319 synovitis 9.8
320 scleredema adultorum 9.8
321 thymoma 9.8
322 teratoma 9.8
323 gastric adenocarcinoma 9.8
324 plasmacytoma 9.8
325 liver disease 9.8
326 hypertrichosis 9.8
327 pneumonia 9.8
328 lymphopenia 9.8
329 neuroblastoma 9.8
330 end stage renal failure 9.8
331 peritonitis 9.8
332 intestinal obstruction 9.8
333 collagen disease 9.8
334 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.8
335 malignant histiocytosis 9.8
336 crohn's disease 9.8
337 leishmaniasis 9.8
338 visceral leishmaniasis 9.8
339 erythromelalgia 9.8
340 plasma cell leukemia 9.8
341 polyarteritis nodosa 9.8
342 hemophilia 9.8
343 acquired hemophilia 9.8
344 acquired hemophilia a 9.8
345 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
346 homologous wasting disease 9.8
347 dysphagia 9.8
348 tremor 9.8
349 posttransplant acute limbic encephalitis 9.8
350 systemic autoimmune disease 9.8
351 glial tumor 9.8
352 rapidly involuting congenital hemangioma 9.8
353 acute liver failure 9.8
354 rare tumor 9.8
355 pheochromocytoma 9.8
356 meningioma, radiation-induced 9.8
357 meningioma, familial 9.8
358 adrenal gland pheochromocytoma 9.8
359 brain meningioma 9.8
360 spinal meningioma 9.8
361 dysentery 9.8
362 pericarditis 9.8
363 liver sarcoma 9.8
364 hemoglobinopathy 9.8
365 secretory meningioma 9.8
366 lymphoplasmacyte-rich meningioma 9.8
367 tubular adenocarcinoma 9.8
368 hyperthyroidism 9.8
369 toxoplasmosis 9.8
370 acquired pure red cell aplasia 9.8
371 amaurosis fugax 9.8
372 cytomegalic inclusion disease 9.8
373 hemoglobin c-beta-thalassemia syndrome 9.8
374 vulva squamous cell carcinoma 9.8 MIR223 MEG3
375 neurofibromatosis, type ii 9.7
376 spondyloarthropathy 1 9.7
377 leri-weill dyschondrosteosis 9.7
378 elliptocytosis 2 9.7
379 esophageal cancer 9.7
380 felty syndrome 9.7
381 hypercholesterolemia, familial, 1 9.7
382 renal cell carcinoma, nonpapillary 9.7
383 hypertriglyceridemia, familial 9.7
384 lipomatosis, multiple 9.7
385 chromosome 5q deletion syndrome 9.7
386 nondisjunction 9.7
387 myositis 9.7
388 neurofibromatosis, type iv, of riccardi 9.7
389 noonan syndrome 1 9.7
390 osteoporosis 9.7
391 ovarian cancer 9.7
392 pelger-huet anomaly 9.7
393 platelet aggregation, spontaneous 9.7
394 prostate cancer 9.7
395 pulmonary fibrosis, idiopathic 9.7
396 retinal detachment 9.7
397 retinoblastoma 9.7
398 sarcoidosis 1 9.7
399 trichorhinophalangeal syndrome, type i 9.7
400 suppressor of tumorigenicity 3 9.7
401 abetalipoproteinemia 9.7
402 australia antigen 9.7
403 lung cancer 9.7
404 cryptorchidism, unilateral or bilateral 9.7
405 factor vii deficiency 9.7
406 gaucher disease, type i 9.7
407 ghosal hematodiaphyseal dysplasia 9.7
408 macrocephaly/megalencephaly syndrome, autosomal recessive 9.7
409 familial mediterranean fever 9.7
410 myasthenia gravis 9.7
411 ocular motor apraxia 9.7
412 hypertrophic osteoarthropathy, primary, autosomal recessive, 1 9.7
413 pyruvate kinase deficiency of red cells 9.7
414 hemophagocytic lymphohistiocytosis, familial, 1 9.7
415 revesz syndrome 9.7
416 sea-blue histiocyte disease 9.7
417 alpha-thalassemia myelodysplasia syndrome 9.7
418 thrombocytopenia with beta-thalassemia, x-linked 9.7
419 retinitis pigmentosa 11 9.7
420 stroke, ischemic 9.7
421 homocysteinemia 9.7
422 body mass index quantitative trait locus 1 9.7
423 hypereosinophilic syndrome, idiopathic 9.7
424 noonan syndrome-like disorder with loose anagen hair 1 9.7
425 juvenile myelomonocytic leukemia 9.7
426 parathyroid carcinoma 9.7
427 myocardial infarction 9.7
428 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.7
429 malaria 9.7
430 bone mineral density quantitative trait locus 8 9.7
431 lung cancer susceptibility 3 9.7
432 bone mineral density quantitative trait locus 15 9.7
433 aspergillosis 9.7
434 hypertrophic osteoarthropathy, primary, autosomal recessive, 2 9.7
435 thrombocythemia 3 9.7
436 membranous nephropathy 9.7
437 human herpesvirus 8 9.7
438 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.7
439 steel syndrome 9.7
440 carbonic anhydrase va deficiency, hyperammonemia due to 9.7
441 takenouchi-kosaki syndrome 9.7
442 elliptocytosis 3 9.7
443 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
444 bacterial sepsis 9.7
445 aspiration pneumonia 9.7
446 periventricular nodular heterotopia 9.7
447 adult t-cell leukemia 9.7
448 inflammatory bowel disease 9.7
449 hypochromic microcytic anemia 9.7
450 lymphoplasmacytic lymphoma 9.7
451 metabolic acidosis 9.7
452 zollinger-ellison syndrome 9.7
453 follicular lymphoma 9.7
454 aphasia 9.7
455 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 9.7
456 colitis 9.7
457 crohn's colitis 9.7
458 crest syndrome 9.7
459 sclerosteosis 9.7
460 ptosis 9.7
461 bone resorption disease 9.7
462 hepatic veno-occlusive disease 9.7
463 castleman disease 9.7
464 endocarditis 9.7
465 secondary hypertrophic osteoarthropathy 9.7
466 nasopharyngitis 9.7
467 interstitial nephritis 9.7
468 thrombotic thrombocytopenic purpura 9.7
469 hydrocephalus 9.7
470 brucellosis 9.7
471 oculomotor nerve paralysis 9.7
472 multicentric reticulohistiocytosis 9.7
473 visual epilepsy 9.7
474 ecthyma 9.7
475 cryptococcosis 9.7
476 inflammatory spondylopathy 9.7
477 pulmonary alveolar proteinosis 9.7
478 low compliance bladder 9.7
479 dengue disease 9.7
480 bronchopneumonia 9.7
481 von willebrand's disease 9.7
482 hepatic coma 9.7
483 leiomyoma 9.7
484 telangiectasis 9.7
485 uveitis 9.7
486 hepatic encephalopathy 9.7
487 congenital hypoplastic anemia 9.7
488 coccidioidomycosis 9.7
489 osteopetrosis 9.7
490 hepatic infarction 9.7
491 toxic shock syndrome 9.7
492 hypothyroidism 9.7
493 papilledema 9.7
494 nodular nonsuppurative panniculitis 9.7
495 rheumatic disease 9.7
496 cystitis 9.7
497 retinal vein occlusion 9.7
498 islet cell tumor 9.7
499 leiomyosarcoma 9.7
500 hyperinsulinism 9.7
501 enthesopathy 9.7
502 intestinal perforation 9.7
503 hepatitis 9.7
504 motor neuron disease 9.7
505 polyclonal hypergammaglobulinemia 9.7
506 arteriosclerosis 9.7
507 acromegaly 9.7
508 central retinal vein occlusion 9.7
509 thrombophilia 9.7
510 splenic disease 9.7
511 hemangioma 9.7
512 kidney cancer 9.7
513 parasitic protozoa infectious disease 9.7
514 erythropoietin polycythemia 9.7
515 endometriosis 9.7
516 anuria 9.7
517 adenocarcinoma 9.7
518 glioblastoma multiforme 9.7
519 malignant glioma 9.7
520 interstitial lung disease 9.7
521 gallbladder cancer 9.7
522 myelitis 9.7
523 ischemia 9.7
524 spindle cell thymoma 9.7
525 thymic carcinoma 9.7
526 mammary paget's disease 9.7
527 cellulitis 9.7
528 linitis plastica 9.7
529 syphilis 9.7
530 myopathy 9.7
531 erdheim-chester disease 9.7
532 pustulosis of palm and sole 9.7
533 seminoma 9.7
534 familial retinoblastoma 9.7
535 uremia 9.7
536 calciphylaxis 9.7
537 embryoma 9.7
538 proliferative glomerulonephritis 9.7
539 mesangial proliferative glomerulonephritis 9.7
540 ureteral obstruction 9.7
541 gastrinoma 9.7
542 third cranial nerve disease 9.7
543 adenosine deaminase deficiency 9.7
544 posterior myocardial infarction 9.7
545 paraplegia 9.7
546 thyroid hyalinizing trabecular adenoma 9.7
547 spondylitis 9.7
548 cerebrovascular disease 9.7
549 t-cell leukemia 9.7
550 thyroiditis 9.7
551 peptic ulcer disease 9.7
552 septic arthritis 9.7
553 appendicitis 9.7
554 pyridoxine deficiency anemia 9.7
555 polyhydramnios 9.7
556 lung disease 9.7
557 herpes zoster 9.7
558 herpes simplex 9.7
559 hodgkin's lymphoma, lymphocytic depletion 9.7
560 in situ carcinoma 9.7
561 rubella 9.7
562 psoriasis 9.7
563 splenic tuberculosis 9.7
564 diabetes mellitus 9.7
565 exophthalmos 9.7
566 hypopituitarism 9.7
567 acute myocardial infarction 9.7
568 diabetes insipidus 9.7
569 intracranial hypertension 9.7
570 cholangitis 9.7
571 smoldering myeloma 9.7
572 stomatitis 9.7
573 gata1-related x-linked cytopenia 9.7
574 hypertrophic cardiomyopathy 9.7
575 sickle cell disease 9.7
576 acquired angioedema 9.7
577 acute erythroid leukemia 9.7
578 acute myeloblastic leukemia with maturation 9.7
579 anaplastic plasmacytoma 9.7
580 aquagenic pruritus 9.7
581 bowen's disease 9.7
582 chromosome 20q deletion 9.7
583 congenital hemolytic anemia 9.7
584 cutis verticis gyrata 9.7
585 fibrillary glomerulonephritis 9.7
586 hemangioendothelioma 9.7
587 human t-cell leukemia virus type 1 9.7
588 lymphomatoid granulomatosis 9.7
589 madelung deformity 9.7
590 mosaic trisomy 8 9.7
591 mycobacterium kansasii 9.7
592 nodular regenerative hyperplasia 9.7
593 post-transplant lymphoproliferative disease 9.7
594 posterior urethral valves 9.7
595 pseudo pelger-huet anomaly 9.7
596 pseudo-turner syndrome 9.7
597 spastic paraparesis 9.7
598 stenotrophomonas maltophilia infection 9.7
599 stevens-johnson syndrome/toxic epidermal necrolysis 9.7
600 telangiectasia macularis eruptive perstans 9.7
601 thrombasthenia 9.7
602 cryptogenic cirrhosis 9.7
603 aneurysm 9.7
604 back pain 9.7
605 cerebral beriberi 9.7
606 hypertonia 9.7
607 hypotonia 9.7
608 megalencephaly 9.7
609 seizure disorder 9.7
610 epithelioid hemangioendothelioma 9.7
611 primary hemophagocytic lymphohistiocytosis 9.7
612 partial duplication of chromosome 1 9.7
613 ring chromosome 9.7
614 rasopathy 9.7
615 diffuse alveolar hemorrhage 9.7
616 histiocytic sarcoma 9.7
617 large granular lymphocyte leukemia 9.7
618 hepatosplenic t-cell lymphoma 9.7
619 polyploidy 9.7
620 monosomy 22 9.7
621 glomerular disease 9.7
622 overgrowth syndrome 9.7
623 intravascular large b-cell lymphoma 9.7
624 acute megakaryoblastic leukemia in down syndrome 9.7

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to Myelofibrosis

Symptoms & Phenotypes for Myelofibrosis

Human phenotypes related to Myelofibrosis:

58 31 (showing 38, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
7 hepatosplenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001433
8 abnormal megakaryocyte morphology 58 31 frequent (33%) Frequent (79-30%) HP:0012143
9 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
10 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
11 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
12 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
13 easy fatigability 58 31 occasional (7.5%) Occasional (29-5%) HP:0003388
14 thrombocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001894
15 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
16 petechiae 58 31 occasional (7.5%) Occasional (29-5%) HP:0000967
17 arterial thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004420
18 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
19 low-grade fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0011134
20 extramedullary hematopoiesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001978
21 poikilocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004447
22 bone marrow hypercellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031020
23 ecchymosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0031364
24 flank pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0030157
25 cachexia 58 31 very rare (1%) Very rare (<4-1%) HP:0004326
26 increased lactate dehydrogenase activity 58 31 very rare (1%) Very rare (<4-1%) HP:0025435
27 hemangioma 58 31 very rare (1%) Very rare (<4-1%) HP:0001028
28 hematological neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0004377
29 fever 58 31 Occasional (29-5%) HP:0001945
30 purpura 58 31 Occasional (29-5%) HP:0000979
31 abnormal bleeding 58 Occasional (29-5%)
32 abnormal thrombosis 58 Occasional (29-5%)
33 abnormality of blood and blood-forming tissues 58 Frequent (79-30%)
34 abnormality of bone marrow cell morphology 58 Very frequent (99-80%)
35 autoimmune antibody positivity 58 Excluded (0%)
36 constitutional symptom 58 Frequent (79-30%)
37 myeloproliferative disorder 31 HP:0005547
38 myelofibrosis 31 HP:0011974

Symptoms via clinical synopsis from OMIM:

56
Hematology:
myeloproliferative disease
reduced hemopoiesis
generalized bone marrow fibrosis
no hemophagocytosis

Clinical features from OMIM:

254450

MGI Mouse Phenotypes related to Myelofibrosis:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.36 CD177 EPO FGF2 GATA1 JAK2 KIT

Drugs & Therapeutics for Myelofibrosis

Drugs for Myelofibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 331, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
3
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
6
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
7 Hormones Phase 4
8 Vitamins Phase 4
9 Trace Elements Phase 4
10 Micronutrients Phase 4
11 Nutrients Phase 4
12 Mitogens Phase 4
13 Calcium, Dietary Phase 4
14 Endothelial Growth Factors Phase 4
15 Ergocalciferols Phase 4
16 Vitamin D2 Phase 4
17 Angiogenesis Inducing Agents Phase 4
18 Calciferol Phase 4
19
Tin Phase 4 7440-31-5
20 Tin Fluorides Phase 4
21 Fluorides Phase 4
22 Cariostatic Agents Phase 4
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Ribavirin Approved Phase 3 36791-04-5 37542
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Dalteparin Approved Phase 3 9005-49-6
28
Captopril Approved Phase 3 62571-86-2 44093
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
31
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
32
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
33
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
34
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
35
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
36
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
37
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
38
Peginterferon alfa-2b Approved Phase 3 215647-85-1, 99210-65-8
39
Anagrelide Approved Phase 3 68475-42-3 2182
40
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
41
Hydroxyurea Approved Phase 3 127-07-1 3657
42
Mercaptopurine Approved Phase 3 50-44-2 667490
43
Danazol Approved Phase 3 17230-88-5 28417
44
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
45
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
46
Polyestradiol phosphate Approved Phase 3 28014-46-2
47
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
48
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
49
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
50
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
51
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
52 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
53 Anesthetics, Dissociative Phase 3
54
protease inhibitors Phase 3
55 HIV Protease Inhibitors Phase 3
56 Antihypertensive Agents Phase 3
57 Antipsychotic Agents Phase 3
58 Central Nervous System Depressants Phase 3
59 Tranquilizing Agents Phase 3
60 Analgesics, Opioid Phase 3
61 Neurotransmitter Agents Phase 3
62 Psychotropic Drugs Phase 3
63 Antipruritics Phase 3
64 Anti-Anxiety Agents Phase 3
65 Serotonin Agents Phase 3
66 Serotonin Antagonists Phase 3
67 Analgesics Phase 3
68 valacyclovir Phase 3
69 Cola Phase 3
70 Heparin, Low-Molecular-Weight Phase 3
71 Angiotensin-Converting Enzyme Inhibitors Phase 3
72 Cytochrome P-450 CYP3A Inhibitors Phase 3
73
Hydroxyitraconazole Phase 3
74 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
75 Steroid Synthesis Inhibitors Phase 3
76 Narcotics Phase 3
77 Excitatory Amino Acid Antagonists Phase 3
78 Excitatory Amino Acids Phase 3
79 Anesthetics Phase 3
80 Adjuvants, Anesthesia Phase 3
81 Anesthetics, General Phase 3
82 Anesthetics, Intravenous Phase 3
83 Antiparasitic Agents Phase 3
84 Antiprotozoal Agents Phase 3
85 Liposomal amphotericin B Phase 3
86 Immunoglobulin Fc Fragments Phase 3
87 Protein Kinase Inhibitors Phase 3
88 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
89 Interferon-alpha Phase 3
90 Interferon alpha-2 Phase 3
91 Androgens Phase 3
92 Estrogens Phase 3
93 Estrogen Receptor Antagonists Phase 3
94 Estrogen Antagonists Phase 3
95 Hepcidins Phase 3
96 glucocorticoids Phase 3
97 Topoisomerase Inhibitors Phase 3
98 Janus Kinase Inhibitors Phase 3
99 interferons Phase 3
100 Contraceptive Agents Phase 3
101 Norgestimate, ethinyl estradiol drug combination Phase 3
102 Estradiol 17 beta-cypionate Phase 3
103 Contraceptives, Oral, Combined Phase 3
104 Contraceptives, Oral Phase 3
105 Estradiol 3-benzoate Phase 3
106
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
107
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
108
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
109
Zoledronic Acid Approved Phase 2 118072-93-8 68740
110
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
111
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
112
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
113
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
114
Idarubicin Approved Phase 2 58957-92-9 42890
115
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
116
tannic acid Approved Phase 1, Phase 2 1401-55-4
117
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
118
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
119
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
120
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033